MDMA na ptsd, schizofrenie i depresje (?)

[Unknown]

Potencjał terapeutyczny MDMA [2010] The Wright Institute:

Conclusion

Despite a substantial body of literature suggesting the positive, life-affirming, and potentially spiritually and psychologically healing properties of the MDMA experience, the efficacy of MDMA for treating certain psychological disorders cannot be confirmed until the results of randomized, double-blinded, placebo-controlled clinical trials have been published. Until then, questions remain as to whether the benefits do indeed outweigh the risks involved in implementing a drug that can be damaging to the brain if used irresponsibly. It is also impossible to prove with anecdotal evidence alone that the psychological gains afforded by a singular experience, no matter how profound, doindeed endure over time. What also needs to be considered are the risks involved in the post-MDMA recovery period, where temporary neurochemical depletion has been shown to cause depressed mood, irritability, and brooding (Liechti et al., 2001). Further research is needed to assess whether this hang-over effect could potentially undo or cancel out emotional insights.

Although fears and stigma surrounding ecstasy use endure, fears that for yearshave served to keep this much needed research from being permitted, the tides seem to beturning as of late. In the past few years, MDMA has received a great deal of publicity in a variety of media reporting on its therapeutic potential. There are currently a number of sophisticated clinical studies underway in the U.S., Switzerland, Israel, Canada, Jordan,and Spain investigating the use of MDMA in the treatment of PTSD, as well as one study being conducted at McLean Hospital investigating MDMA-assisted psychotherapy in thetreatment of anxiety secondary to advance stage cancer (Multidisciplinary Association for Psychedelic Studies, 2010).

But these few studies are only the beginning, considering the amount of research that will be needed to explore MDMA’s full clinical potential. MDMA has been shown to be useful for a large number of other therapeutic purposes, including couples therapy, drug abuse, vocational rehabilitation, and in the treatment of psychosomatic diseases and schizophrenia (Greer, 1985). Sessa and Nutt (2007) have also suggested its potential for use in treating suicidal depression in the emergency room as an alternative to electroconvulsive therapy. It remains to be seen whether the funding for MDMA will continue to materialize, since pharmaceutical companies have nothing to gain from MDMA. But if the current studies confirm what seems to be a hugely promising tool for psychiatric healing in MDMA, perhaps some government sponsorship will start to materialize in the name of healthcare cost prevention.

Historia ecstasy: ;]